Kan. Admin. Regs. § 28-21-266
Each vial or ampule of injectable amygdalin and each vial or container of tablets or capsules shall contain a package insert with complete description of the product including potency, adverse reactions, contra-indications, dosage recommendations, mode of administration, and other information as may be required. In packaging amygdalin (laetrile) for direct patient usage, a patient package insert must also be enclosed which summarizes the potential risks of the product. All tablets or capsules shall be packaged in child-proof containers. A precautionary label shall be attached to all packaging of injectable amygdalin (laetrile) warning patients against taking the parenteral preparation by mouth, since the high concentration can be rapidly fatal.
Kan. Admin. Regs. § 28-21-266